Search Results - "Meropol, N J"

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer by Cohen, S.J., Punt, C.J.A., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M.A., Mitchell, E., Miller, M.C., Doyle, G.V., Tissing, H., Terstappen, L.W.M.M., Meropol, N.J.

“…Background: We demonstrated that circulating tumor cell (CTC) number at baseline and follow-up is an independent prognostic factor in metastatic colorectal…”
Get full text

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer by Aggarwal, C., Meropol, N.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M.A., Mitchell, E., Miller, M.C., Cohen, S.J.

“…We previously reported results of a prospective trial evaluating the significance of circulating tumor cells (CTCs) in patients with metastatic colorectal…”
Get full text

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200 by Giantonio, BJ, Levy, DE, O'Dwyer, PJ, Meropol, NJ, Catalano, PJ, Benson, AB

“…Aim: Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined…”
Get full text

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer by Dotan, E, Meropol, N J, Zhu, F, Zambito, F, Bove, B, Cai, K Q, Godwin, A K, Golemis, E A, Astsaturov, I, Cohen, S J

“…Background: Increased Aurora kinase A gene copy number ( AURKA-CN ) has been reported in metastatic colorectal cancer (mCRC), with unknown relationship to…”
Get full text

Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer by Cohen, S J, Konski, A A, Putnam, S, Ball, D S, Meyer, J E, Yu, J Q, Astsaturov, I, Marlow, C, Dickens, A, Cade, D N, Meropol, N J

“…Background: This was a prospective single-centre, phase I study to document the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and the recommended…”
Get full text

The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial by Miller, S. M., Hudson, S. V., Egleston, B. L., Manne, S., Buzaglo, J. S., Devarajan, K., Fleisher, L., Millard, J., Solarino, N., Trinastic, J., Meropol, N. J.

“…Background Cancer clinical trials (CCTs) are important tools in the development of improved cancer therapies; yet, participation is low. Key psychosocial…”
Get full text

Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel by ROTHENBERG, Mace L, MEROPOL, Neal J, POPLIN, Elizabeth A, VAN CUTSEM, Eric, WADLER, Scott

“…To review and assign attribution for the causes of early deaths on two National Cancer Institute-sponsored cooperative group studies involving irinotecan and…”
Get full text

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine by Budman, D R, Meropol, N J, Reigner, B, Creaven, P J, Lichtman, S M, Berghorn, E, Behr, J, Gordon, R J, Osterwalder, B, Griffin, T

“…To evaluate the toxicology and pharmacology of an orally active fluoropyrimidine given as a continuous daily dose divided into two portions for 6 weeks, and to…”
Get more information

Attitudinal barriers to participation in oncology clinical trials: factor analysis and correlates of barriers by Manne, S., Kashy, D., Albrecht, T., Wong, Y.-N., Lederman Flamm, A., Benson III, A. B., Miller, S.M., Fleisher, Linda, Buzaglo, J., Roach, N., Katz, M., Ross, E., Collins, M., Poole, D., Raivitch, S., Miller, D.M., Kinzy, T.G., Liu, T., Meropol, N.J.

“…Patient participation in cancer clinical trials is low. Little is known about attitudinal barriers to participation, particularly among patients who may be…”
Get full text

Oral fluoropyrimidines in the treatment of colorectal cancer by Meropol, N.J

“…5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since its initial development 40 years ago. Efforts to improve the…”
Get full text

American Society of Clinical Oncology Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants by HENSLEY, M. L, SCHUCHTER, L. M, NEGRIN, R, SZATROWSKI, T. P, THIGPEN, J. T, VON HOFF, D, WASSERMAN, T. H, WINER, E. P, PFISTER, D. G, LINDLEY, C, MEROPOL, N. J, COHEN, G. I, BRODER, G, GRADISHAR, W. J, GREEN, D. M, LANGDON, R. J, MITCHELL, R. B

“…Because toxicities associated with chemotherapy and radiotherapy can adversely affect short- and long-term patient quality of life, can limit the dose and…”
Get full text

Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565 by VENOOK, A. P, EGORIN, M. J, RATAIN, M. J, ROSNER, G. L, HOLLIS, D, MANI, S, HAWKINS, M, BYRD, J, HOHL, R, BUDMAN, D, MEROPOL, N. J

“…To ascertain if hepatic or renal dysfunction leads to increased toxicity at a given dose of gemcitabine and to characterize the pharmacokinetics of gemcitabine…”
Get full text

Patient-physician discordance in goals of care for patients with advanced cancer by Douglas, S L, Daly, B J, Meropol, N J, Lipson, A R

“…Shared decision-making at end of life (eol) requires discussions about goals of care and prioritization of length of life compared with quality of life. The…”
Get full text

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours by Zurita, A J, Khajavi, M, Wu, H-K, Tye, L, Huang, X, Kulke, M H, Lenz, H-J, Meropol, N J, Carley, W, DePrimo, S E, Lin, E, Wang, X, Harmon, C S, Heymach, J V

“…Background: Sunitinib is approved worldwide for treatment of advanced pancreatic neuroendocrine tumours (pNET), but no validated markers exist to predict…”
Get full text

Impact of Quality of Life on Patient Expectations Regarding Phase I Clinical Trials by CHENG, J. D, HITT, J, KOCZWARA, B, SCHULMAN, K. A, BURNETT, C. B, GASKIN, D. J, ROWLAND, J. H, MEROPOL, N. J

“…Quality of life (QOL) is increasingly recognized as a critical cancer-treatment outcome measure, but little is known about the impact of QOL on the patient…”
Get full text

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity by MEROPOL, N. J, PORTER, M, CALIGIURI, M. A, BLUMENSON, L. E, LINDEMANN, M. J, PEREZ, R. P, VAICKUS, L, LOEWEN, G. M, CREAVEN, P. J, WILKES, K. A, GIEDLIN, M. A

“…We aimed to determine the toxicity and immunological effects of daily s.c. administered low-dose interleukin (IL) 2. Adult cancer patients received a single…”
Get full text

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing by Meropol, N J, Barresi, G M, Fehniger, T A, Hitt, J, Franklin, M, Caligiuri, M A

“…Natural killer (NK) cells may be expanded in vivo with a prolonged course of daily subcutaneous interleukin-2 (IL-2). However, cellular activation requires…”
Get full text

Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods by Mandelblatt, J S, Bierman, A S, Gold, K, Zhang, Y, Ng, J H, Maserejian, N, Maserejan, N, Hwang, Y T, Meropol, N J, Hadley, J, Silliman, R A

“…The burden of illness can influence treatment decisions, but there are limited data comparing the performance of different illness burden measures. We assessed…”
Get full text

Paradoxical Correlations of Cyclin-dependent Kinase Inhibitors p21waf1/cip1 and p27kip1 in Metastatic Colorectal Carcinoma by CHENG, J. D, WERNESS, B. A, BABB, J. S, MEROPOL, N. J

“…The cyclin-dependent kinase inhibitors (CDIs) p27kip1 and p21waf1/cip1 are key cell cycle-negative regulatory enzymes. The objective of this study was to…”
Get full text

A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer by MEROPOL, N. J, RUSTUM, Y. M, PETRELLI, N. J, RODRIGUEZ-BIGAS, M, FRANK, C, HO, D. H, KUROWSKI, M, CREAVEN, P. J

“…A phase I and pharmacokinetics study of oral uracil, ftorafur, and leucovorin was performed in patients with advanced cancer. Uracil plus ftorafur (UFT) was…”
Get full text